Newswire (Published: Thursday, June 20, 2019, Received: Thursday, June 20, 2019, 5:19:47 PM CDT)

Word Count: 509

2019 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news reporting from Pittsburgh, United States, by NewsRx journalists, research stated, “Multiparametric magnetic resonance imaging (mpMRI) may improve prostate cancer risk stratification and decrease the need for repeat biopsies in men on prostate cancer active surveillance (AS). However, the impact of mpMRI on AS-related healthcare spending has not been established.”

The news correspondents obtained a quote from the research from the University of Pittsburgh Medical Center, “To characterize the impact of mpMRI on AS-related Medicare expenditures. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare files, we identified men 66 yr old with localized prostate cancer diagnosed during 2008-2013. With a validated algorithm, we classified men into AS with and without mpMRI groups. We then determined Medicare spending on AS in each group using inflation-adjusted, price-standardized Medicare payments for AS-related procedures (ie, prostate-specific antigen [PSA] tests, prostate biopsies, biopsy complications, and mpMRI). Multivariable median regression compared Medicare spending on AS for men who received mpMRI and those who did not. We identified 9081 men on AS with a median follow-up of 45 mo (interquartile range 29-64 mo). Thirteen percent (N=1225) received mpMRI. On multivariable median regression, receipt of mpMRI was associated with an additional $447 (95% confidence interval $409-487) in Medicare spending per year. We observed greater frequency of AS-related procedures and higher spending for identical procedures (eg, PSA or prostate biopsy) in the mpMRI group than in the non-mpMRI group (all p<0.001). Among Medicare beneficiaries on AS, mpMRI is associated with additional annual Medicare spending. Future studies are needed to determine optimal use of mpMRI during AS to maximize value. Prostate magnetic resonance imaging (MRI) helps physicians determine which prostate cancers are aggressive and which can be monitored safely. We studied whether using MRI during prostate cancer monitoring (also called active surveillance) resulted in increased healthcare spending.”

According to the news reporters, the research concluded: “There was a modest increase in spending, but this may be worthwhile if the use of MRI allows physicians to monitor prostate cancer more accurately.”

For more information on this research see: Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance. European Urology Focus, 2019;():.

Our news journalists report that additional information may be obtained by contacting L.C. Macleod, Dept. of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. Additional authors for this research include J.G. Yabes, M.M. Fam, J. Bandari, M. Yu, A. Maganty, A. Furlan, C.P. Filson, B.J. Davies and B.L Jacobs.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.euf.2019.04.008. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of Pittsburgh Medical Center

Places

North America
United States
Americas
Pennsylvania
Pittsburgh

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Healthcare Management
            National and Subsidized Healthcare
      Medical Specialties and Practices
            Urology